What is Zacks Research’s Forecast for CPRX FY2025 Earnings?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities research analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of $2.02 for the year, down from their previous estimate of $2.07. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ FY2026 earnings at $2.25 EPS and FY2027 earnings at $2.37 EPS.

A number of other research analysts have also issued reports on CPRX. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Bank of America reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Finally, Stephens reaffirmed an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Stock Down 0.1 %

Shares of Catalyst Pharmaceuticals stock opened at $25.72 on Monday. The company has a 50 day moving average price of $22.53 and a 200 day moving average price of $21.72. The firm has a market capitalization of $3.12 billion, a P/E ratio of 21.80, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals has a 52 week low of $14.47 and a 52 week high of $26.16.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company’s stock, valued at $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after acquiring an additional 33,888 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Catalyst Pharmaceuticals by 13.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock worth $8,710,000 after acquiring an additional 50,888 shares in the last quarter. Wellington Management Group LLP purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth about $1,185,000. Finally, Redhawk Wealth Advisors Inc. purchased a new position in Catalyst Pharmaceuticals in the fourth quarter worth approximately $1,273,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.